Navtemadlin clinical trials

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

This study looks at adding a new medicine, navtemadlin, to an existing treatment, ruxolitinib, for people with myelofibrosis. It aims to see if this combination works better for those whose myelofibrosis isn't fully controlled by ruxolitinib alone.